Wie hoch ist der Preis für Ensysce Biosciences, Inc. (ENSC)

Preis für Ensysce Biosciences, Inc. (ENSC) ist $0.2483

Wie hoch ist die Marktkapitalisierung für Ensysce Biosciences, Inc. (ENSC)

Marktkapitalisierung für Ensysce Biosciences, Inc. (ENSC) ist $2.30M

Ensysce Biosciences, Inc. (ENSC) KUV

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

Jahr	P/S-Verhältnis	ändert
2026 (TTM)	6.35	132.71%
2024	2.73	-83.08%
2023	16.14	67.59%
2022	9.63	-97.61%
2021	402.60	-99.21%
2020	50.77K	-60.81%
2019	129.53K	0.00%
2018	0.00	0.00%
2017	0.00	0.00%

Jahr

P/S-Verhältnis

ändert

2026 (TTM)

6.35

132.71%

2024

2.73

-83.08%

2023

16.14

67.59%

2022

9.63

-97.61%

2021

402.60

-99.21%

2020

50.77K

-60.81%

2019

129.53K

0.00%

2018

0.00

0.00%

2017

0.00

0.00%

Unternehmen	P/S-Verhältnis	P/S-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.44	64.40%	US
Moderna, Inc. MRNA.US	26.12	311.20%	US
Argenx SE ARGX.US	12.01	89.00%	NL
CSL Limited CSL.AX	3.76	-40.89%	AU
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

P/S-Verhältnis

P/S-Verhältnis-Differenz

Land